A Study to Investigate Outcomes and Management Effectiveness of Cardiogenic Shock II Patients


About this study

The purpose of this study is to develop a registry of patients with clinical cardiogenic shock (CS) in order to allow better definition of several key issues regarding cardiogenic shock.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients meeting criteria for cardiogenic shock during the study period of August 1, 2019 to July 31, 2022.
  • Cardiogenic shock criteria defined as:
    • Systolic blood pressure < 90 mm Hg or mean arterial blood pressure 30 mm Hg below baseline for at least 30 minutes despite volume resuscitation and/or vasoactive therapy; and
    • Evidence of end-organ hypoperfusion (altered mental status, oliguria with urine output <30 mL/hour, cool extremities, lactate >2.0 mmol/L); or
    • Pulmonary edema.
  • The etiology of cardiogenic shock can be categorized into one of the following subtypes:
    • Ischemic (acute myocardial infarction, ischemic cardiomyopathy), myocardial (end-stage heart failure, myocarditis), post-cardiotomy, cardiac tamponade, pulmonary thromboembolus.
  • Subjects requiring mechanical circulatory support for one of the CS subtypes listed above.
  • Age ≥ 18 years old.
  • Consent for study participation has been obtained.

Exclusion Criteria: 

  • Lack of consent for study participation.
  • Shock due to causes other than cardiogenic shock (e.g., sepsis, serious ventricular arrhythmias not due to myocardial ischemia or heart failure, neurogenic, anaphylactic, hemorrhagic/hypovolemic).
  • Shock with unwitnessed out of hospital cardiac arrest.
  • Severe non-cardiac morbidity with expected survival of < 6 months (e.g., malignancy, end-stage liver disease, severe chronic lung disease, severe CNS morbidity).
  • Admission occurring outside the study period.
  • Refusal of active treatment.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Jacob Jentzer, M.D.

Open for enrollment

Contact information:

Misty Radosevich M.D.



More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer